1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Illumina, Inc.

Illumina, Inc.

ILU.DE
Illumina, Inc.DE flagDeutsche Börse
124.28
EUR
+0.74
- -
18.80BMarket Cap
Illumina, Inc.
ILU.DE
(Deutsche Börse)

Recent

price

124.28

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
7.3
8.55
9.34
11.36
13.73
15.33
16.34
18.85
22.67
24.1
22.03
30.17
29.2
28.51
27.5
28.02
28.46
Revenue per Share
1.01
0.7
1.23
1
2.61
3.19
3.15
4.97
5.62
6.82
4.46
5.08
-28.05
-7.35
-7.69
5.48
5.53
Basic EPS, GAAP
1.75
2.26
1.71
2.37
2.65
4.44
3.46
3.86
5.76
5.73
6.06
2.25
-0.47
1.78
4.46
6.01
6.31
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.24
-0.54
0.68
1.68
4.15
7.07
10.13
15.47
20.99
27.68
32.14
36.58
7.29
-0.11
-7.8
-2.52
-1.66
Book Value per Share
6.87
5.24
6.66
3.83
3.12
5.68
8.53
12.35
19.24
24.79
24.86
2.51
0.48
1.31
6.07
9.03
6.23
Tangible Book Value per Share
124
123
123
125
136
145
147
146
147
147
147
150
157
158
159
155
154
Basic Weighted Avg Shares
903
1,056
1,149
1,421
1,861
2,220
2,398
2,752
3,333
3,543
3,239
4,526
4,584
4,504
4,372
4,343
4,393
Sales/Revenue/Turnover
22.5
23.72
22.33
17.88
23.82
28.47
24.1
22.02
26.49
27.8
17.91
-2.72
7.72
-4.93
13.72
18.81
19.6
Operating Margin (%)
42
69
65
98
113
127
141
156
179
188
187
251
394
432
354
270
270
Depreciation Expense
125
87
151
125
353
462
463
726
826
1,002
656
762
-4,404
-1,161
-1,223
850
853
Net Income, GAAP
32.63
34.89
32.05
21.35
21.26
21.44
23.71
35
12.53
11.45
23.36
13.8
- -
- -
- -
21.73
19.53
Effective Tax Rate (%)
13.83
8.21
13.17
8.82
18.98
20.81
19.31
26.38
24.78
28.28
20.25
16.84
-96.07
-25.78
-27.97
19.57
19.42
Profit Margin (%)
724
1,318
1,482
1,295
1,167
1,486
1,613
2,234
2,686
3,786
3,239
1,620
788
1,039
1,199
1,704
1,172
Working Capital
- -
807
805
839
987
1,016
1,056
1,182
890
1,836
1,344
2,469
2,231
2,176
2,044
1,976
1,965
LT Debt
1,198
1,075
1,319
1,533
1,463
1,849
2,270
2,749
3,845
4,613
4,694
10,740
6,599
5,745
2,373
2,723
2,676
Total Equity
10.28
9.57
8.54
8.66
13.36
17.16
13.42
10.22
15.36
13.96
6.71
-1.06
- -
- -
- -
12.22
13.36
Return on Invested Capital (%)
167.21
24.34
21.23
15.61
26.34
25.12
21.07
24.8
20.99
19.07
11.03
11.11
- -
- -
- -
52.41
49.31
Return on Capital (%)
- -
- -
- -
85.28
91.47
58.2
36.87
38.77
30.92
28.01
14.92
14.92
-132.83
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1,076
577
579
LT Borrowings
994
1,490
1,490
LT Finance Leases
506
486
475
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
153
153
152
Market Capitalization
14,697
21,007
19,086

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
2,796
3,289
2,738
Cash, Cash Equivalents & STI
1,278
1,633
1,155
Accounts Receivable, Net
729
854
738
Inventories
590
564
611
Total Current Liabilities
1,962
1,585
1,566
Payables & Accruals
420
489
536
ST Debt
1,076
577
579
Deferred Revenue
234
270
269

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.89%
6.67%
14.75%
Free Cash Flow
-43.7%
-96.5%
31.31%
Net Income, GAAP
-84.2%
-179.92%
-169.5%
Sales/Revenue/Turnover
7.73%
7.13%
-0.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,076
1,112
1,080
1,104
4,372
2025
1,041
1,059
1,084
1,159
4,343
2026
1,091
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.79
-12.5
4.43
1.18
-7.69
2025
0.82
1.5
- -
2.18
5.48
2026
0.88
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Instituto Hermes Pardini S.A. (PARD3.SA)
bioMérieux S.A. (BMXMF)
Check-Cap Ltd. Ordinary Share (MBAI)
BioNexus Gene Lab Corp. (BGLC)
Sonic Healthcare Limited (SKHHY)
PharmChem, Inc. (PCHM)
Business
Illumina, Inc. Illumina, Inc. develops, manufactures, and markets integrated systems for genetic and genomic analysis, including next-generation sequencing platforms, microarray technologies, and related consumables; it offers solutions for multiomics, including DNA sequencing, genotyping, gene expression profiling, proteomics, spatial transcriptomics, single-cell analysis, CRISPR technologies, epigenetics, and data analytics software. The company provides high-throughput systems such as the NovaSeq X Series, mid-throughput and benchtop platforms like NextSeq and MiSeq, sequencing kits and reagents, microarray kits, clinical research products, molecular biology reagents, accessory products, and informatics tools; it serves customers in life sciences research, oncology, reproductive health, genetic and rare diseases, microbiology, agrigenomics, drug development, and emerging segments through its Core Illumina and diagnostics units. Founded in 1998 and headquartered in San Diego, California, Illumina operates globally across the Americas, Europe, Middle East, Africa, China, and Asia-Pacific, serving genomic research institutes, clinical organizations, government labs, pharmaceutical, and biotechnology firms in more than 165 countries with an installed base exceeding 22,000 instruments. Recent developments include the June 2025 agreement to acquire SomaLogic from Standard BioTools for $350 million in cash plus up to $75 million in milestones and royalties to accelerate its proteomics business and multiomics strategy; a January 2025 partnership with NVIDIA, IQVIA, and Mayo Clinic to advance next-generation genomics, multiomics analysis, and drug discovery using AI-enabled workflows; the July 2024 acquisition of Fluent BioSciences to expand single-cell research capabilities; and ongoing innovations highlighted at the 2025 AGBT conference, such as enhanced end-to-end workflow solutions and BioInsight for pharmaceutical applications, targeting high single-digit revenue growth and a 26% operating margin by 2027.